![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PEREGRINE IN LICENSE DEAL WITH MEDAREX
PEREGRINE IN LICENSE DEAL WITH MEDAREX
August 26, 2005
Cancer drug developer Peregrine Pharmaceuticals Inc. said Thursday that it licensed certain rights to its tumor-targeting technology to biopharmaceutical company Medarex Inc. The company did not disclose financial details in a news release, but said it will receive an upfront payment and annual maintenance fees along with potential milestone and royalty payments. In return, Princeton, N.J.-based Medarex receives the right to develop its prostate-specific antibody along with certain drugs to treat a range of solid tumors.
Forbes (http://www.forbes.com/business/healthcare/feeds/ap/2005/08/25/ap2192333.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct